Filtered By:
Infectious Disease: Meningitis
Drug: Beta-Blockers
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 45 results found since Jan 2013.
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cardiac failure in a child with tuberculous meningitis as a complication of Paroxysmal sympathetic hyperactivity
CONCLUSIONS: PSH assessment tool has benefits such as monitoring the patient, evaluating response to treatment and early diagnosing PSH patients.PMID:35611428 | DOI:10.24953/turkjped.2020.3609
Source: The Turkish Journal of Pediatrics - May 25, 2022 Category: Pediatrics Authors: P ınar Yazıcı Özkaya E şe Eda Turanlı Hatice Feray Ar ı Serap Kurt B ülent Karapınar Source Type: research
